Valuation: Imugene Limited

Capitalization 114M 77.59M 66.04M 61.33M 57.5M 107M 7.11B 700M 277M 3.36B 291M 285M 12.28B P/E ratio 2026 *
-1.98x
P/E ratio 2027 * -2.67x
Enterprise value 114M 77.59M 66.04M 61.33M 57.5M 107M 7.11B 700M 277M 3.36B 291M 285M 12.28B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
87%
Yield 2026 *
-
Yield 2027 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+2.90%
1 week+9.23%
Current month-2.74%
1 month+12.70%
3 months-5.33%
6 months+10.94%
Current year-2.74%
More quotes
1 week 0.32
Extreme 0.32
0.36
1 month 0.31
Extreme 0.31
0.41
Current year 0.32
Extreme 0.32
0.41
1 year 0.24
Extreme 0.245
1.5
3 years 0.24
Extreme 0.245
5.44
5 years 0.24
Extreme 0.245
21.25
10 years 0.24
Extreme 0.238
21.25
More quotes
Manager TitleAgeSince
Chief Executive Officer - 31/10/2016
Director of Finance/CFO - 03/03/2025
Chief Tech/Sci/R&D Officer - 31/08/2023
Director TitleAgeSince
Chairman 70 30/10/2012
Director/Board Member - 27/03/2018
Director/Board Member 66 22/04/2019
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+2.90%+9.23%-73.23%-93.26% 75.4M
+0.04%-0.68%-4.77%+12.20% 49.33B
-1.28%-0.50%+14.81%+3.39% 40.71B
+0.43%+0.79%+53.37%+26.71% 37.49B
+1.92%+0.71%+22.15%+42.46% 31.07B
+0.01%-0.79%+190.06%+334.24% 22.97B
-4.25%-4.90%+67.00%+142.56% 17.08B
Average -0.38%+0.13%+38.48%+66.90% 28.39B
Weighted average by Cap. -0.85%-0.72%+43.08%+66.25%
See all sector performances

Financials

2026 *2027 *
Net sales - -
Net income -52.7M -36.02M -30.66M -28.47M -26.69M -49.71M -3.3B -325M -129M -1.56B -135M -132M -5.7B -52.7M -36.02M -30.66M -28.47M -26.69M -49.71M -3.3B -325M -129M -1.56B -135M -132M -5.7B
Net Debt - -
More financial data * Estimated data
Logo Imugene Limited
Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.
Employees
5
More about the company
Date Price Change Volume
23/01/26 0.3550 $ +2.90% 851,919
22/01/26 0.3450 $ +4.55% 1,878,516
21/01/26 0.3300 $ -1.49% 770,508
20/01/26 0.3350 $ +1.52% 1,426,953
19/01/26 0.3300 $ -1.49% 1,232,310

Delayed Quote Australian S.E., January 23, 2026 at 05:10 am

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3550AUD
Average target price
0.8200AUD
Spread / Average Target
+130.99%
Consensus

Quarterly revenue - Rate of surprise